Antibody-based cancer drugs: developing antibody therapeutic approaches to deliver individualized cancer drugs.
Kalland
Terje
T
Biovitrum AB, Stockholm, Sweden. terje.kalland@biovitrum.com
D020533:Angiogenesis Inhibitors / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology; D000077544:Panitumumab; D018089:Superantigens / Q000276:immunology / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D018089:Superantigens; D000077544:Panitumumab; D066246:ErbB Receptors